S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80

MEI Pharma Stock Forecast, Price & News

+0.05 (+9.32%)
(As of 07/6/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
2.43 million shs
Average Volume
5.02 million shs
Market Capitalization
$77.99 million
P/E Ratio
Dividend Yield
Price Target

MEI Pharma MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
774.0% Upside
$5.13 Price Target
Short Interest
15.50% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.86mentions of MEI Pharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($0.69) to ($0.62) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.08 out of 5 stars

Medical Sector

283rd out of 1,433 stocks

Pharmaceutical Preparations Industry

125th out of 683 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive MEIP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MEI Pharma and its competitors with MarketBeat's FREE daily newsletter.

MEI Pharma logo

About MEI Pharma (NASDAQ:MEIP) Stock

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

MEIP Stock News Headlines

A Bigger Opportunity For Growth…
A smaller stock with a relatively low market cap often outperforms a larger company stock with a much higher market cap… And when an investor is spending fewer dollars for a stock purchase there’s a bigger opportunity for growth. Click Here for Our Top 5 Microcap Stocks.
StockNews.com Initiates Coverage on MEI Pharma (NASDAQ:MEIP)
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Pacira (PCRX) Q1 Earnings Miss Estimates
Expert Ratings For MEI Pharma
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Previous Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
6 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$25.53 million
Book Value
$0.44 per share


Free Float
Market Cap
$77.99 million

MEI Pharma Frequently Asked Questions

Should I buy or sell MEI Pharma stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MEI Pharma stock.
View analyst ratings for MEI Pharma
or view top-rated stocks.

What is MEI Pharma's stock price forecast for 2022?

6 brokerages have issued twelve-month price targets for MEI Pharma's shares. Their MEIP stock forecasts range from $1.00 to $20.00. On average, they expect MEI Pharma's stock price to reach $5.13 in the next year. This suggests a possible upside of 774.0% from the stock's current price.
View analysts' price targets for MEI Pharma
or view top-rated stocks among Wall Street analysts.

How has MEI Pharma's stock performed in 2022?

MEI Pharma's stock was trading at $2.67 on January 1st, 2022. Since then, MEIP shares have decreased by 78.0% and is now trading at $0.5864.
View the best growth stocks for 2022 here

When is MEI Pharma's next earnings date?

MEI Pharma is scheduled to release its next quarterly earnings announcement on Thursday, September 1st 2022.
View our earnings forecast for MEI Pharma

How were MEI Pharma's earnings last quarter?

MEI Pharma, Inc. (NASDAQ:MEIP) posted its quarterly earnings results on Monday, May, 23rd. The company reported ($0.17) EPS for the quarter, meeting analysts' consensus estimates of ($0.17). The firm had revenue of $9.69 million for the quarter, compared to analysts' expectations of $6.25 million. MEI Pharma had a negative net margin of 62.40% and a negative trailing twelve-month return on equity of 71.32%.
View MEI Pharma's earnings history

Who are MEI Pharma's key executives?

MEI Pharma's management team includes the following people:
  • Dr. Daniel P. Gold, Pres, CEO & Director (Age 68, Pay $1.03M)
  • Mr. David M. Urso B.A., Esq., J.D., COO & Gen. Counsel (Age 58, Pay $680.47k)
  • Dr. Robert D. Mass, Strategic Advisor (Age 68, Pay $201.68k)
  • Dr. Richard G. Ghalie, Chief Medical Officer (Age 64, Pay $550.55k)
  • Ms. Virginia Sankey, VP of Fin.
  • Dr. Eric Deng Ph.D., VP of Technical Operations
  • Ms. Tina Clark Beamon Esq., J.D., Chief Compliance Officer
  • Mr. Brian T. Powl, Sr. VP of Marketing
  • Ms. Anne Frese, Chief People Officer
  • Dr. Karen E. Potts Ph.D., Sr. VP of Regulatory Affairs (Age 59)

What other stocks do shareholders of MEI Pharma own?

What is MEI Pharma's stock symbol?

MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."

How do I buy shares of MEI Pharma?

Shares of MEIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MEI Pharma's stock price today?

One share of MEIP stock can currently be purchased for approximately $0.59.

How much money does MEI Pharma make?

MEI Pharma (NASDAQ:MEIP) has a market capitalization of $77.99 million and generates $25.53 million in revenue each year. The company earns $-41,310,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis.

How many employees does MEI Pharma have?

MEI Pharma employs 76 workers across the globe.

How can I contact MEI Pharma?

MEI Pharma's mailing address is 11455 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The official website for MEI Pharma is www.meipharma.com. The company can be reached via phone at (858) 369-7100, via email at investor@meipharma.com, or via fax at 302-655-5049.

This page (NASDAQ:MEIP) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.